170 likes | 310 Views
Accelerated Measles Control: Highlights and priorities for South East Asian Region. Anindya Bose, IVD/FHR, SEARO Global Measles and Rubella Management Meeting Salle B, WHO Headquarters, Geneva, Switzerland 15-17 March, 2011. Overview. Regional Measles and Rubella Goals
E N D
Accelerated Measles Control: Highlights and priorities for South East Asian Region Anindya Bose, IVD/FHR, SEARO Global Measles and Rubella Management Meeting Salle B, WHO Headquarters, Geneva, Switzerland 15-17 March, 2011
Overview • Regional Measles and Rubella Goals • Progress towards the Goals: • Immunization coverage • Surveillance data • Linkages with other programme interventions • Strengths in SEA Region • 2011: plans and budgets • Major challenges in the region and barriers to achieving the goals • Advocacy plans and opportunities
Regional consultative processes for accelerated measles control and Current regional goals • High level preparatory (HLP) meeting proposal for consideration of 63rd Regional Committee • Interim goals approved by the 63rd World Health Assembly (May 2010) should be adopted • By 2015 • MCV1 coverage >90% nationally and >80% in all districts • Measles incidence <5/million and maintain that level • Reduce mortality by 95% compared to 2000 • 63rd Regional Committeein Sept 2010 • Endorsed the recommendations made by the HLP meeting
SEAR: Rubella goals (Immunization TAG 2008) Noted that 4 countries (Bhutan, Maldives, Sri Lanka and Thailand) include RCV in their routine EPI. Recommendations: • Remaining countries should strengthen/establish rubella and CRS surveillance. • Countries should review burden of rubella and CRS, build the political and financial commitment to introduce Rubella containing Vaccine (RCV) according to WHO guidelines
1st dose measles vaccine coverage (MCV1) by country*, SEAR, 2009 (Minimum Target 90%) Country *WHO/ UNICEF Estimate
Estimated measles mortality (2000-08), MCV1 coverage and SIA achievements SEAR, 2000 to 2010 46% Reduction 2000-2010: 153 million children immunized through MEASLES SIA
SEAR: Type of vaccine in MCV2 and SIA by 2010 Measles vaccine MMR vaccine
Measles Incidence per million population 2009 (as reported through JRF) Maldives
Linkages & Collaboration with Other Programmes (integration) • Impact on the routine immunization programme • Some countries (e.g. India took a policy decision to keep RI days undisturbed during campaign weeks) • India program looking at effect of measles catch-up activity on RI programme • Integration with polio, other child health programmes • Most countries in SEA Region combine other interventions (OPV, Vit-A) with measles mass campaigns)
SEAR Strengths… 1/2 • Strong and visible political commitment. • National Governments funding measles in RI and catch-up campaign • Major contributions from Govts. Of Bangladesh, Bhutan, DPR Korea, Maldives, Myanmar and Sri Lanka • India: All costs for MCV2 and SIA borne by National Govt. • Vaccine supply and security • At least two countries in the Region have measles vaccine production capacities • Can be scaled up to match additional demand
SEAR Strengths and opportunities … 2/2 • Excellent community acceptance and safety profile of catch-up campaigns • Support from Polio eradication infrastructure in five priority countries • Bangladesh, India, Indonesia, Myanmar and Nepal • Laboratory support to measles surveillance adequate and can be scaled up • Built on Polio laboratories infrastructure plus • Inclusion of new labs for laboratory supported surveillance for measles
Overview • Regional Measles and Rubella Goals • Progress towards the Goals: • Immunization coverage • Surveillance data • Linkages with other programme interventions • Strengths in SEA Region • 2011: plans and budgets • Major challenges in the region and barriers to achieving the goals • Advocacy plans and opportunities
Measles SIA plans for 2011 • 2011: SEAR Plans to immunize 56 million children in 3 countries * • India: catch-up campaign targeting 38 million covering whole of 9 states • Indonesia: Follow-up targeting 12 million in 17 provinces • MMR: Follow-up targeting 6 million in two phases covering whole country * Provisional
Budget to support measles SIA and surveillance in 2011 • Contributions from National Govts. for measles SIA and surveillance for 2011 • $ 78 million (IND, INO and MMR) • Does not take into account moneys spent by Govt. in RI systems and services • Budget for WHO and UNICEF support to measles SIA and surveillance (in USD million)
Challenges for the Region … 1/2 • Large Target population and MCV1 coverage • 5 countries (IND, INO, MMR, NEP, TLS) with nearly 83% of the population will need to increase MCV1 coverage by 8-20% to reach 90% level nationally • Building strong political commitment and full country ownership when there are competing health priorities • Adequate resource (equipment, staff, training and supervision) commitment to ensure • Safe injection practices and waste disposal. • System for monitoring and responding to Adverse Events Following Immunization (AEFI) • Establishing a high quality surveillance system that meets surveillance performance indicators
Challenges: Funding support for SIA and surveillance in 2011 (2/2) • 2011 SIA plans in Region for 56 million children • INO (12 mln), IND (38 mln), MMR (6 mln) • Support needed (in order of priority) • Myanmar for vaccines, operational costs, surveillance and technical support (USD 5.2 million) • WHO regional office for surveillance and technical support. (USD 0.5 million) • Technical support for India (USD 5 million) • Surveillance Costs (Bangladesh, India, Indonesia and Nepal) (USD 4.2 million) • Support for Indonesia towards operational costs for campaigns and technical support. (USD 5.4 million) • Total requirement: ~ USD 20.5 million
Summary • 63rd Regional Committee has recommended that countries work towards the interim milestones towards measles elimination • At least 8 out of 11 countries (except IND, INO and TLS) have reached or can reach these milestones on current program performance • In 2010, India has introduced 2nd dose of measles (state specific strategies) and has launched a campaign to immunize 134 million children • Funding shortfall remains an immediate challenge • Continued advocacy and support needed for countries to sustain gains and take the next step towards and beyond elimination milestones Thank You